Tousignant Jennifer sold $348K of VRDN

Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares of Viridian Therapeutics, Inc.\DE (VRDN) at $24.50 ($0.35M total) across 2 trades on 2026-08-19.

Original reporting
SEC EDGAR · Tousignant Jennifer
Published Aug 21, 2026, 12:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRDN
Neutral
medium confidence
Mentioned
$VRDN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRDNNeutralLow
01

Why it matters

The disclosure is the first public report of this insider transaction, but the modest size limits material impact.

02

Market read

Small insider sell; unlikely to move the stock significantly.

03

What to watch

No other insiders sold; company may still have strong pipeline.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑08‑19

Background

Form 4 filing by Viridian Therapeutics' Chief Legal Officer discloses a complete exit from the company's stock.

Company-level read

Ticker impact

$VRDNNeutralMedium confidence
Context

Chief Legal Officer sold 14,212 shares for $348,194, reducing holdings to zero.

Expected impact

Minimal short-term impact; possible slight downward pressure.

Evidence & confidence

The sale is a primary Form 4 filing but involves a small amount relative to market cap, limiting trading relevance.

Market effects

None significant for biotech sector.

No regional effect.

Limited to VRDN shareholders.

Counterpoint

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Viridian Therapeutics, Inc.

    Biotech firm listed on NASDAQ under VRDN.

  • Jennifer Tousignant

    Chief Legal Officer of Viridian Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.